Literature DB >> 3498566

Serum IgD elevation is an early marker of B cell activation during infection with the human immunodeficiency viruses.

H Mizuma1, S Zolla-Pazner, S Litwin, W el-Sadr, S Sharpe, B Zehr, S Weiss, W C Saxinger, M Marmor.   

Abstract

Serum IgD levels in individuals infected with the human immunodeficiency viruses (HIV) were studied as a means of monitoring the character and timing of B cell activation in individuals with this infection. Significantly increased levels of IgD were characteristic of homosexual men who were HIV seropositive but asymptomatic or mildly symptomatic. The hyper IgD globulinaemia became progressively more pronounced in patients with increasingly severe infection and reached its most marked level in patients with AIDS-related complex (ARC). In ARC patients, IgD levels were increased 8.8-fold above normal which was disproportionately greater than the 2.4-fold increase in IgG, the 1.8-fold increase in IgA and the 1.6-fold increase in IgM. IgD levels declined in AIDS patients (although remained elevated compared to controls). The data suggest that an unusual type of B cell activation is responsible for the unique pattern of hypergammaglobulinaemia seen in this disease and that the B cell activation occurs early in the pathogenesis of HIV infection, often before development of symptoms, and continues throughout the course of infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498566      PMCID: PMC1542677     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

1.  Characterization of antigen-binding receptors in vitro. I. An equilibrium method for measuring antigen binding in murine cells.

Authors:  M J Benfari; S R Cooperband; F L Moolten
Journal:  J Immunol       Date:  1977-10       Impact factor: 5.422

2.  Increased serum IgD concentrations in patients with Hodgkin's disease.

Authors:  G Corte; M Ferrarini; P Tonda; A Bargellesi
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

3.  Persistent increased immunoglobulin M in treated narcotic addition. Association with liver disease and continuing heroin use.

Authors:  P Cushman
Journal:  J Allergy Clin Immunol       Date:  1973-08       Impact factor: 10.793

4.  Immunoglobulin classes of antibody to hepatitis B core antigen.

Authors:  W J Brzosko; B Mikulska; J Cianciara; J Babiuch
Journal:  J Infect Dis       Date:  1975-07       Impact factor: 5.226

5.  Correlation of serum IgD level with clinical and histologic parameters in Hodgkin disease.

Authors:  G Corte; A M Ferraris; J K Rees; A Bargellesi; F G Hayhoe
Journal:  Blood       Date:  1978-11       Impact factor: 22.113

6.  Acquired immune deficiency syndrome. AIDS: the widening gyre.

Authors:  J E Groopman; M S Gottlieb
Journal:  Nature       Date:  1983 Jun 16-22       Impact factor: 49.962

7.  Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma.

Authors:  R E Stahl; A Friedman-Kien; R Dubin; M Marmor; S Zolla-Pazner
Journal:  Am J Med       Date:  1982-08       Impact factor: 4.965

8.  Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers.

Authors:  A Rubinstein; M Sicklick; A Gupta; L Bernstein; N Klein; E Rubinstein; I Spigland; L Fruchter; N Litman; H Lee; M Hollander
Journal:  JAMA       Date:  1983-05-06       Impact factor: 56.272

9.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

10.  Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS.

Authors:  J Schüpbach; M Popovic; R V Gilden; M A Gonda; M G Sarngadharan; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  18 in total

Review 1.  Immunoglobulin D: properties, measurement, and clinical relevance.

Authors:  A O Vladutiu
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 2.  New insights into the enigma of immunoglobulin D.

Authors:  Kang Chen; Andrea Cerutti
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

3.  The truth on IgD in the ploy of immune surveillance and inflammation.

Authors:  Donato Rigante
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

4.  Hyperimmunoglobulinaemia D and periodic fever mimicking familial Mediterranean fever in the Mediterranean.

Authors:  R Topaloğlu; U Saatçi
Journal:  Postgrad Med J       Date:  1991-05       Impact factor: 2.401

5.  Alterations in peripheral blood B-cell populations in SHIV89.6P-infected macaques (Macacca fascicularis).

Authors:  Heather M Kling; Timothy W Shipley; Karen A Norris
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

Review 6.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

7.  Specific serum immunoglobulin D, detected by antibody capture enzyme-linked immunosorbent assay (ELISA), in cytomegalovirus infection.

Authors:  J Mortensen; S L Nielsen; I Sørensen; H K Andersen
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

8.  Altered IgG-subclass distribution in lymph node cells and serum of adults infected with human immunodeficiency virus (HIV).

Authors:  F Müller; S S Frøland; P Brandtzaeg
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

9.  IgD production and other lymphocyte functions in HIV infection: immaturity and activation of B cells at different clinical stages.

Authors:  L A Rogers; S M Forster; A J Pinching
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

10.  Immunoglobulin D switching can occur through homologous recombination in human B cells.

Authors:  M B White; C J Word; C G Humphries; F R Blattner; P W Tucker
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.